Review Article
Comparing the Therapeutic Potential of Stem Cells and their Secretory Products in Regenerative Medicine
Table 3
Cell-free treatment in clinical trials for various diseases.
| Target disease | Cell | Clinical trials identifier | Administration | Dosage | Results |
| COVID-19 | MSC-derived exosomes | NCT04491240 | Inhalation | exosomes | No observable side effects in 30 days. Improvement in overall treatment is not insignificant compared to standard therapy. | Chronic ulcer | MSC conditioned media | NCT04134676 | Topical | Unknown | Not available | Keloid | Umbilical cord-MSC conditioned medium | NCT04326959 | Intralesional | 1 mL/cm3 | Not available | Knee osteoarthritis | MSC conditioned medium | NCT04314661 | Intra-articular injection | 2 mL 2 weeks after MSC cells | Not available | SARS-CoV-2-associated pneumonia | MSC-derived exosomes | NCT04276987 | Inhalation | vesicles/3 mL for 5 days | Not available | Multiple organ failures after surgical repair of aortic dissection | MSC-derived exosomes | NCT04356300 | Intravenous | 150 mg exosomes for 2 weeks | Ongoing | Chronic low back pain | Platelet-rich plasma with exosomes | NCT04849429 | Intrathecal | 2 mL | Ongoing | Cerebrovascular disorders | MSC-derived exosomes | NCT03384433 | Intravenous | Not available | Ongoing | COVID-19 | MSC conditioned medium | NCT04753476 | Intramuscular | 0.5-1 mL (3 doses) | Ongoing |
|
|